MHRP researchers and collaborators are scheduled to speak and present at the 9th IAS Conference on HIV Science taking place July 23-26 in Paris.
MHRP Researchers Speaking in Special Sessions:
Sunday, July 23
IAS HIV Cure & Cancer forum
- 10:30-12:00 - Panelist Dr. Jintanat Anaworanich, "Clinical Trial Design and Participation"
Monday, July 24
2:30 - 5:00 - Workshop co-facilitator, Dr. Jintanat Ananworanich, “HIV Cure in Men and Women: From Mechanisms of HIV Latency and Persistence to Potential Therapeutic Strategies”
Tuesday, July 25
11:00-12:30: Bridging Session: “Primary HIV Infection and Early Treatment”
- 11:19 a.m.: Dr. Lydia Trautmann, “New insights into the immune response and viral reservoir during PHI”
- 12:01 p.m.: Dr. Jintanat Ananworanich, “The future of early diagnosis and intervention during PHI “
2:30-4:00: Oral Abstract session: “Antiretroviral Therapy - ART: Season Two”
- 3:45 p.m.: Dr. Trevor Crowell, “HIV-specific broadly-neutralizing monoclonal antibody, VRC01, minimally impacts time to viral rebound following treatment interruption in virologically-suppressed, HIV-infected participants who initiated antiretroviral therapy during acute HIV infection “
Wednesday, July 26
1:00-2:30 p.m.: Special session, IAS Members Meeting and Joep Lange Memorial Lecture”
- 1:25 p.m.: Dr. Jintanat Ananworanich, “Joep Lange Memorial lecture”
Poster exhibits and collaborator abstracts:
Program number MOLBPEA07
Rasmi Thomas (MHRP), “Increased levels of HIV-1 specific IgG antibody in the presence of HLA-DPB1*13 in three HIV-1 vaccine trials”
Program number MOLBPEA03
Margaret C. Costanzo (MHRP), “Higher levels of NK cell phenotypic diversity and transcriptional activation prior to HIV-1 infection are associated with increased set point viral load”
Program number MOPEA0067
Remi Fromentin (collaborator), “In vivo massive expansion of a T-cell clone carrying a defective HIV genome: implication for the measurement of the HIV reservoir”
Program number MOPEA0081:
Nicolas Chomont (collaborator), “Low frequencies of HIV-infected cells in blood, colon and lymph node at the earliest stage of acute infection (Fiebig I)”
Program number MOPEB0246
Claudia Cicala (collaborator), “HIV transmission and disease progression are linked to the frequency of α4β7+ CD4+ T cells”
Program number MOPEC0716
Rebecca G. Nowak (collaborator), “Synergistic impact of sexual stigma and psychosocial well-being on HIV testing among Nigerian men who have sex with men: a mixed methods study”
Program number TUPEC0770
Judith Harbertson (collaborator), “Longitudinal analysis of sexual risk behavior, alcohol misuse and mental health disorders associated with STIs among U.S. military personnel across a shipboard deployment”
Program number TUPEC0831
Rebecca Nowak (collaborator), “Leveraging individual and ego-network predictors of HIV incidence among Nigerian Men who have sex with men to guide network-level interventions”
Program number WEAA0205
Susana Valente (collaborator), “Eradication without reactivation: suppression of HIV-1 transcription and reactivation from latency by a Tat inhibitor” (*oral abstract)
Program number WEPEA0186
Richard Apps (collaborator), “HLA-C is downregulated by most primary clones of HIV-1, and variation between these viruses is more pronounced for downregulation of HLA-C than HLA-A/B”
Program number WEPEB0535
Irini Sereti (collaborator), “IL-27 is an independent predictor of IRIS: results of a multicenter international prospective study”
Program number WEPEC0974
Kathryn Peebles (collaborator), “HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine”
Program number WEPED1463
Jean Njab (collaborator), “HIV treatment cascade assessment of a community-based test and start model for key populations in Lagos, Nigeria: where are the gaps?”